Trending Up0.0228 (4.5591%)
  • Bid / Lots
    0.5000/ 3
  • Ask / Lots
    0.5400/ 4
  • Open / Previous Close
    0.5050 / 0.5001
  • Day Range
    Low 0.5049
    High 0.5438
  • 52 Week Range
    Low 0.4800
    High 2.3600
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.5001
09:32 ET36320.5111
09:37 ET1000.5116
09:46 ET10000.5051
09:51 ET30400.5049
09:53 ET5000.505
09:57 ET2730.5187
10:06 ET10000.5145
10:13 ET3000.5144
10:36 ET42600.505
10:54 ET20000.51
11:05 ET2010.5113
11:14 ET1000.5101
11:39 ET10000.5133
11:41 ET1500.519999
11:45 ET1940.5113
11:48 ET4250.514999
11:54 ET2500.52
12:14 ET10000.515001
12:17 ET5000.52
12:24 ET9100.514999
12:46 ET1000.5101
12:51 ET7000.5199
01:38 ET7000.519
01:51 ET8000.5191
02:03 ET52760.5191
02:09 ET2000.519
02:12 ET15700.5192
02:14 ET14080.52
02:16 ET38010.52
02:18 ET1000.5191
02:34 ET1190.519
02:36 ET20000.524501
02:43 ET31000.53
02:45 ET9750.5216
02:48 ET2880.5438
02:50 ET10000.5437
02:59 ET1000.5366
03:01 ET5330.5245
03:06 ET1000.5366
03:12 ET25000.5265
03:19 ET6750.5252
03:21 ET5000.53315
03:32 ET2000.5366
03:33 ET5000.5255
03:44 ET1000.53325
03:50 ET2000.5332
04:00 ET67050.5229
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCRDL
Cardiol Therapeutics Inc
As of 2022-12-03

Company Information

Cardiol Therapeutics Inc. (Cardiol) is a Canada-based clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

Contact Information

602-2265 Upper Middle Road EastOAKVILLE, ON, Canada L6H 0G5


No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.